Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

It was approved to reduce hospitalisation in heart failure patients in 2019, and then got the go-ahead for use in patients with heart failure with reduced ejection fraction (HFrEF) in 2020 on the ...

Biome Analytics has launched the Heart Failure Performance Module, a new addition to its Foundations Reporting platform. This tool is designed to help healthcare professionals improve heart ...